Compare Kraft Heinz Co (KHC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Novavax Inc — how do they compare? Kraft Heinz Co trades at $22.29 (market cap $26.66B), while Novavax Inc trades at $12.73 (market cap $1.82B). The key difference: Kraft Heinz Co is far larger — about 14.6× Novavax Inc's market cap, and Kraft Heinz Co pays a 7.12% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Novavax Inc for 59 Days on average.
| KHC | NVAX | |
|---|---|---|
Market Cap | $26.66B | $1.82B |
Volume | 31,300,109 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $12.56 |
52-Week Low | $21.21 | $6.22 |
Typical Hold Time | 129 Days | 59 Days |
Enterprise Value | $42.98B | $1.39B |
Dividend Yield | 7.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.27, up 1.32% today, with a bearish technical signal but positive earnings beats in recent quarters. The company faces fundamental headwinds, including a net loss of $5.85 billion in 2025 and a negative net income margin of -13.64%, though operating cash flow remains strong at $4.46 billion. Recent news highlights turnaround efforts, such as new product launches and a $700 million reinvestment plan, amid a high dividend yield and mixed analyst sentiment.
The outlook is cautious due to profitability challenges and high debt, but the stock's low valuation (P/E of 13.04, P/B of 0.74) and consistent cash flow offer potential for value investors. Risks include sustained volume declines and competitive pressures, while the consensus price target of $24.50 suggests modest upside if turnaround initiatives gain traction.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
